AJP - Regulatory, Integrative and Comparative Physiology, Vol 258, Issue 3 736-R742, Copyright © 1990 by American Physiological Society

ARTICLES

Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro

C. Wahlestedt, R. Hakanson, C. A. Vaz and Z. Zukowska-Grojec
Department of Neurology, Cornell University Medical College, New York, New York 10021.

Norepinephrine (NE)-evoked vasoconstrictor and pressor responses are reduced after prolonged exposure; such desensitization is observed both clinically and experimentally. The vasoconstrictor neuropeptide Y (NPY) coexists with NE in perivascular sympathetic nerves, and the results of both in vivo and in vitro studies have indicated functional cooperation between NE and NPY. We propose that NPY becomes increasingly important in situations of high sympathetic activity associated with blunted NE responses. Prolonged NE infusion in conscious rats resulted in adrenergic desensitization; however, NPY administration restored the responsiveness to NE. In naive rats, NE greatly enhanced the pressor action of NPY. An analogous phenomenon was observed in the rabbit isolated pulmonary artery, which failed to respond to NPY unless preexposed to NE; this action of NE was only partly inhibited by conventional adrenoceptor and Ca2+ influx blockade. Conversely, NPY enhanced NE-evoked constriction, in particular when the alpha-adrenoceptor reserve was eliminated. It is proposed that threshold synergism, in part caused by converging stimulation of phospholipase C, accounts for much of the NPY/NE cooperativity. We conclude that 1) NPY and NE cooperate to produce vasoconstriction, both in vivo and in vitro; 2) NPY has the capacity to reverse adrenergic desensitization but not vice versa; 3) NE enhances NPY-evoked vasoconstriction, in part independently of conventional adrenoceptor blockade; 4) threshold synergism phenomena, but not "receptor-receptor interactions," account for (most of) the observed NPY/NE cooperation; and 5) when present, alpha-adrenoceptor reserve prevents the lowering of the NE threshold by NPY.

This article has been cited by other articles:

				D. Miller, K. Forrester, C. Leonard, P. Salo, and R. C. Bray ACL deficiency impairs the vasoconstrictive efficacy of neuropeptide Y and phenylephrine in articular tissues: a laser speckle perfusion imaging study J Appl Physiol, January 1, 2005; 98(1): 329 - 333. [Abstract] [Full Text] [PDF]

				D. P. Stephens, A. R. Saad, L. A. T. Bennett, W. A. Kosiba, and J. M. Johnson Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1404 - H1409. [Abstract] [Full Text] [PDF]

				M. Michalkiewicz, T. Michalkiewicz, D. L. Kreulen, and S. J. McDougall Increased blood pressure responses in neuropeptide Y transgenic rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2001; 281(2): R417 - R426. [Abstract] [Full Text] [PDF]

				J. Wahren, K. Ekberg, J. Johansson, M. Henriksson, A. Pramanik, B.-L. Johansson, R. Rigler, and H. Jornvall Role of C-peptide in human physiology Am J Physiol Endocrinol Metab, May 1, 2000; 278(5): E759 - E768. [Abstract] [Full Text] [PDF]

				V. Cortés, M.V. Donoso, N. Brown, R. Fanjul, C. López, A. Fournier, and J. P. Huidobro-Toro Synergism between Neuropeptide Y and Norepinephrine Highlights Sympathetic Cotransmission: Studies in Rat Arterial Mesenteric Bed with Neuropeptide Y, Analogs, and BIBP 3226 J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1313 - 1322. [Abstract] [Full Text]

				L. V. Schuerch, L. M. Linder, E. Grouzmann, and W. E. Haefeli Human neuropeptide Y potentiates alpha 1-adrenergic blood pressure responses in vivo Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H760 - H766. [Abstract] [Full Text] [PDF]

				S. A. Lang and M. B. Maron Effect of neuropeptide Y on hemodynamics of the rabbit lung J Appl Physiol, February 1, 1998; 84(2): 618 - 623. [Abstract] [Full Text] [PDF]

				L. Linder, B. M. Lautenschlager, and W. E. Haefeli Subconstrictor Doses of Neuropeptide Y Potentiate {alpha}1-Adrenergic Venoconstriction In Vivo Hypertension, September 1, 1996; 28(3): 483 - 487. [Abstract] [Full Text]